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Abstract
Background and Aims—The effect of the inflammatory bowel diseases (IBD) on menstrual 
function is largely unknown. The aims of this study were to determine whether changes in 
menstrual function occur in the year prior to IBD diagnosis or in the initial years after diagnosis.
Methods—Women aged 18 and above in the Ocean State Crohn's and Colitis Area Registry with 
at least 2 years of follow-up were eligible for this study. All subjects were enrolled within 6 
months of IBD diagnosis and followed prospectively. Menstrual cycle characteristics were 
retrospectively assessed. To assess for changes over time, general linear models for correlated data 
were used for continuous outcomes and generalized estimating equations were used for discrete 
outcomes.
Results—121 subjects were studied. Twenty-five percent of subjects experienced a change in 
cycle interval in the year prior to IBD diagnosis and 21% experienced a change in duration of 
flow. Among women with dysmenorrhea, 40% experienced a change in the intensity of their 
menstrual pain and 31% experienced a change in its duration. Overall cycle regularity increased 
over time.. Quality of life (QOL) was significantly lower in women without regular cycles across 
all time points.
Conclusions—Changes in menstrual function occur frequently in the year prior to IBD 
diagnosis; therefore screening for menstrual irregularities should be considered in women with 
newly diagnosed IBD. Patients can be reassured that cycles typically become more regular over 
time.
Introduction
The relationship between the inflammatory bowel diseases (IBD) and menstrual function has 
not been fully explored. Although prior studies have examined the gastrointestinal (GI) 
symptoms of women with IBD in relation to the menstrual cycle, in comparison, no study 
has adequately addressed how a diagnosis of IBD affects menstrual function (1-3). Given 
that menstrual disturbances can be a source of stress and morbidity, clarification of the 
effects of IBD on the menstrual cycle is needed.
With regards to the effects of the menstrual cycle on IBD, an initial retrospective study by 
Kane and colleagues found the prevalence of diarrhea to be increased in women with IBD 
and irritable bowel syndrome during both the premenstrual and menstrual phases of the 
cycle compared with healthy controls (1). A more recent study by Bernstein and colleagues 
confirmed that women with Crohn's disease (CD) are more likely to experience diarrhea 
than healthy controls during the premenstrual phase of the cycle and that women with CD or 
ulcerative colitis (UC) are more likely to experience diarrhea during menstruation (2). A 
third study by Parlak and colleagues using a prospective evaluation found that the GI 
symptoms of women with IBD follow a cyclic pattern across the menstrual cycle and that 
this pattern is mediated by disease activity and medication use (3). Furthermore, it showed 
that independent of disease activity women with IBD experience greater GI symptoms 
during menstruation compared to healthy controls. In total, these studies suggest that the 
hormonal fluctuations of the menstrual cycle affect the GI symptoms of women with IBD.
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Regarding the impact of IBD on menstrual function, it is largely unknown whether women 
experience changes in their cycle or in the pain associated with menstruation due to IBD. In 
comparison, many other disease processes such as asthma and epilepsy are known to 
aggravate menstrual symptoms possibly due to changes in prostaglandin release, the 
immune system, and estrogen and progesterone levels (4, 5). Furthermore, autoimmune 
diseases such as systemic lupus erythematosus have been associated with a high frequency 
of menstrual disturbances due to disease activity, anti-ovarian antibodies, and side effects 
from treatment (6, 7).
Common menstrual abnormalities include painful menstruation (i.e. dysmenorrhea), 
abnormal uterine bleeding (menorrhagia and metrorrhagia), and irregularities in menstrual 
frequency (polymenorrhea, oligomenorrhea, and amenorrhea), (8). It has been suggested that 
the presence of any of these problems should elicit careful evaluation as they may be 
representative of significant pathology that can impact a woman's future reproductive health 
or current general health and well being (9). Appropriate and early management may, in 
turn, minimize future complications in women's reproductive ability (10). This is of 
particular importance in IBD as the majority of patients with UC and CD are affected during 
their peak reproductive years (11).
The aims of this study were: 1) to determine if women in an incident cohort of IBD 
experience changes in their menstrual cycle in the year preceding diagnosis and determine 
the nature of those changes and 2) to determine whether women with established IBD 
experience menstrual cycle changes in the first 2 years after diagnosis.
Methods
Participants and Procedures
Women ages 18 and above enrolled in the Ocean State Crohn's and Colitis Area Registry 
(OSCCAR) with a minimum of 2 years of follow-up were eligible for this study. OSCCAR 
is a prospective, community-based incident cohort of IBD based in the state of Rhode Island 
that was established in 2008. Subjects enrolled in OSCCAR have UC, CD, or indeterminate 
colitis (IC) based on endoscopy, radiology, and/or pathology. Eligible subjects must be 
enrolled within 6 months of diagnosis, with a median time to enrollment for adults of 
approximately 90 days from the date of diagnosis.
OSCCAR has been approved by the Institutional Review Boards at Lifespan/Rhode Island 
Hospital, Massachusetts General Hospital, the Icahn School of Medicine at Mount Sinai, and 
the University of Wisconsin School of Medicine and Public Health.
Subjects in OSCCAR undergo assessment of symptoms using a comprehensive symptom 
inventory, disease activity as measured by the Harvey-Bradshaw Index (HBI) (12) for 
subjects with CD or Simple Clinical Colitis Index (SCCAI) (13) for subjects with UC or IC, 
medication use, surgical history, general and disease-specific HRQOL as measured by 
Inflammatory Bowel Disease Questionnaire (IBDQ) (14) at the time of enrollment and then 
every 6 to 12 months, depending on the outcome being measured. In addition to these 
outcomes, adult female subjects also undergo retrospective assessment of several of the 
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critical dimensions to describe menstrual symptoms, including length of cycle (defined as 
number of days from day 1 of one period until day 1 of the subsequent cycle), duration of 
flow (defined as number of days of bleeding), and cycle regularity (defined as regular, fairly 
regular, or irregular based on the predictability of the onset of menses) at baseline and then 
yearly. Questions pertaining to these dimensions have been recommended to assist in the 
diagnosis of abnormal uterine bleeding and in the description of patients' experiences, in 
terms of symptom and symptom impact, with menstrual bleeding (15). Subjects are also 
queried about dysmenorrhea and onset of amenorrhea using an interviewer-administered 
questionnaire at study entry and then yearly
Changes in menstrual cycle characteristics over the past 12 months are also assessed using 
yes/no questions. Subjects who answer “yes” to experiencing a change in their cycle length 
are asked to specify whether the interval between periods has become shorter, longer, 
irregular (defined as some cycles longer and some cycles shorter), or had undergone another 
change. Subjects who answer “yes” to experiencing a change in the duration of flow are 
asked to specify whether the duration of bleeding has become shorter, longer, irregular 
(defined as some cycles with a greater number of days of bleeding and some cycles with a 
fewer number of days of bleeding), or had experienced another change.
Subjects with dysmenorrhea are also asked if they experienced a change in the intensity of 
their menstrual pain over the past 12 months and asked to qualify the change using 
following possible choices: more intense pain, less intense pain, no change in intensity of 
pain. Similarly, subjects with dysmenorrhea are asked if they experienced a change in the 
duration of their menstrual pain and asked to qualify the change using the following possible 
choices: longer duration of pain, shorter duration of pain, no change in duration of pain.
Data analysis
We characterized the demographics, IBD subtype (CD, UC, or IC), disease activity and 
other health measures of the study population. Descriptive statistics, including means and 
standard deviations for continuous variables and frequencies for categorical variables, were 
calculated using standard methods. To assess for changes in menstrual cycle characteristics 
over time, a general linear model for correlated data was used for to model duration of flow, 
cycle length, pain duration, and pain severity, and a general estimating equation was used to 
model cycle regularity, while controlling for correlation due to repeated measures within 
patients over time. Covariates of interest included duration (years) after enrollment, steroids 
usage, and disease subtype, where effects from age, body mass index (BMI), and oral 
contraceptive pill (OCP) use were adjusted. We assumed that time of OCP initiation was not 
a confounding factor for changes in menstrual cycle given that the mean differences between 
age at diagnosis of IBD and age at OCP use onset was large (>1 year) for subjects in our 
dataset.
To analyze the effects of medication exposure, we used logistic regression to calculate a 
propensity score for steroid, thiopurine (i.e. azathioprine and 6-mercaptopurine [6-MP]), and 
anti-tumor necrosis alpha (anti-TNFα) use using age, disease activity scores, total number of 
symptoms, and a binary indicator for other medication usage (i.e. steroid, thiopurine or anti-
TNFα) as predictors. The propensity score was used as an adjustor in assessing the effects of 
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these classes of medications (i.e. steroids, thiopurines, or anti-TNFα) on duration of flow, 
length of cycle, cycle regularity, pain with menses, change in intensity of menstrual pain, 
and change in duration of menstrual pain.
A general linear model for correlated data was used to model IBDQ sores while controlling 
for correlation due to repeated measures within patients over time. Covariates of interest 
included continuous year and disease activity scores, where effects from age, BMI and OCP 
use were adjusted. All analyses were conducted using SAS 9.2.
Results
Study Population
Of 176 eligible subjects, 121 (68.8%) completed the menstrual cycle questionnaire at 
baseline (61 [50.4%] CD, 48 [39.7%] UC/IC, 12 [9.9%] data missing or disease subtype 
unknown) (Table 1). The mean age (SD) of the subjects at diagnosis was 41.5 years (15.7) 
and mean (SD) body mass index (BMI) was 27.1 (7.3). With regards to baseline disease 
activity, mean (SD) HBI score for subjects with CD was 2.1 (3.2) and mean (SD) SCCAI 
score for subjects with UC and IC was 1.5 (2.5). Further demographic information, disease 
activity scores, HRQOL scores, IBD medications, and history of OCP use of the population 
at baseline are summarized in Table 1. Menstrual cycle characteristics for the population at 
baseline are summarized in Table 2.
Changes in menstrual cycle prior to IBD diagnosis
Thirty (24.8%) subjects reported that they had experienced a change in their cycle interval in 
the year prior to IBD diagnosis and 25 (20.7%) reported experiencing a change in their 
duration of flow (Table 3). Among women with baseline dysmenorrhea (n= 48), 19 (39.6%) 
experienced a change in the intensity of their menstrual pain over the past 12 months with 
16 reporting that pain was more intense and only 3 reporting that pain was less intense. In 
addition, the duration of menstrual pain changed for 15 (31.3%) subjects with baseline 
dysmenorrhea, with 12 subjects experiencing menstrual pain of increased duration and 3 
experiencing pain of decreased duration.
To control for changes in the menstrual cycle which may be due to perimenopause, we 
compared subjects ages 18-40 (n=54) to subjects over 40 (n=55). This revealed no 
significant differences in the frequency of changes in cycle length or menstrual pain 
intensity or duration in the year prior to diagnosis (data not shown). The difference in the 
proportion of subject who experienced a change in duration of flow was, however, 
significantly different with the older subjects more likely to experience a change (p=0.01).
Changes in menstrual cycle after IBD diagnosis and treatment
After adjusting for age, BMI, and OCP use no changes were found for mean duration of 
flow, length of cycle, or pain with menses over time for the entire cohort (Table 4). Cycle 
regularity, however, was associated with time wherein each year of greater disease duration 
increased the odds of having more regular cycles by 3.53 (95% CI: 1.86, 6.05).
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With regards to the association between medication exposure and menstrual cycle changes, 
cycle regularity was found to be associated with steroid use among subjects of both disease 
subtypes (p=0.048) after adjusting for age, BMI, OCP use, and propensity of steroid use 
(data not shown). After adjusting for other medication exposure (i.e. thiopurine and anti-
TNFα) the relationship between steroid use and cycle regularity was no longer significant 
(Table 4). No significant associations were found between thiopurine and anti-TNFα 
exposure and any of the menstrual cycle outcomes assessed (Table 4).
Changes in menstrual cycle characteristics were not significantly associated with disease 
activity scores in subjects with UC/IC after adjusting for age, BMI and OCP use (Table 4). 
Using a general estimating equation to model the effects of HBI score on changes in 
menstrual flow we found that only duration of flow was significantly associated with disease 
activity in subjects with CD wherein each one unit increase in HBI score decreased the 
probability of having a change in menstrual flow by 0.72 (95% CI: 0.57, 0.93). No 
significant differences were found between CD subjects in remission (defined as HBI ≤ 3) 
and CD subjects with active disease (defined as HBI > 3) or between UC subjects in 
remission (defined as SCCAI < 3) and UC subjects with active disease (defined as SCCAI ≥ 
3) after controlling for age, BMI, and hormone use.
HRQOL analysis
The average IBDQ score was found to significantly increase over time (p<0.0001) by a 
mean (standard error [SE]) of 9.62 (1.84). IBDQ scores were significantly associated with 
cycle regularity (p=0.04) across all years. IBDQ scores were estimated to be 7.2 (3.4) points 
lower when comparing subjects with “fairly regular” cycles to those with “regular” cycles as 
well as when comparing subjects with “irregular” cycles to those with “fairly regular” 
cycles. IBDQ scores were not found to be significantly associated with changes in menstrual 
pain intensity or duration.
Discussion
The menstrual characteristics of women with newly diagnosed and established IBD have 
largely been unstudied. Although evaluating for menstrual disorders is not generally 
considered to be within the purview of gastroenterologists, given that many are associated 
with anovulatory cycles which increase the risk for infertility (16) determining the impact of 
IBD on menstrual function is important for the comprehensive care of women with IBD. 
Using an incident cohort of IBD, we determined that many women experience some change 
in their menstrual cycle in the year preceding IBD diagnosis. Changes in cycle length were 
most common, followed by changes in duration of flow, and changes in menstrual pain. In 
our comparison of younger subjects to subjects over age 40, we found that apart from 
changes in duration of flow that the frequency of menstrual cycle alterations was not 
different between the 2 groups. This suggests that even among young adult women, for 
whom regular and persistent patterns of menstrual cycle length with little variation 
individually are typical (17), menstrual cycle alterations are frequent in the presence of IBD. 
These findings are consistent with prior work which has showed menstrual abnormalities to 
be common among women with IBD (18).
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Although the potential causes of menstrual irregularity are vast, it has been suggested that 
the menstrual cycle be used as an additional vital sign in the assessment of well-being and 
the exclusion of pathological conditions (19). Thus, eliciting whether a woman with 
suspected IBD has experienced changes in her menstrual cycle may provide the clinician 
insight regarding the nature and severity of the underlying disease.
While the specific changes in cycle length and duration of flow were mixed with no clear 
majority of subjects experiencing an increase or decrease in either characteristic, we found 
that among women with baseline dysmenorrhea who experienced a change, the majority 
reported their menstrual pain to be more intense and of longer duration in the year prior to 
IBD diagnosis. This finding may be due to pathophysiologic mechanisms which are 
common to IBD and primary dysmenorrhea. Some authors have speculated that 
prostaglandins which when released from sloughing endometrium during menstruation 
induce uterine contractions and menstrual pain (20) may also play an important role in the 
abdominal pain and diarrhea experienced by patients with IBD due to increased contractility 
of GI smooth muscle (21). Alternatively, this finding may be due to the misperception of 
IBD symptoms as worsening menstrual pain. Given the overlap in symptoms between active 
IBD and dysmenorrhea (e.g. nausea and vomiting, loss of appetite, diarrhea, general aching, 
irritability, sleep disturbances, and depression), symptom confusion may certainly occur. A 
recent study by Saha et al. found that menstrual distress as measured by the Moos' Menstrual 
Distress Questionnaire positively correlated with CD activity scores, suggesting that 
menstrual symptoms may affect perception of IBD activity (22). We postulate that the 
reverse relationship may also be present. That is, symptoms from IBD may be perceived to 
be menses-related GI symptoms. For women with dysmenorrhea and IBD that has yet to be 
diagnosed, this misperception may have important consequences such as prolongation in the 
time to IBD diagnosis and incorrect therapeutic choices. For example, non-steroidal anti-
inflammatory drugs which are first-line therapy for the treatment of dysmenorrhea (23) are 
potential exacerbating factors for IBD and usually are to be avoided (24, 25). It is important 
to note, however, that the majority of women with dysmenorrhea reported no change in 
either the intensity or frequency of their menstrual pain in the year preceding diagnosis.
With regards to changes in the menstrual cycle in women with IBD of at least 1 year 
duration, after controlling for age, BMI and OCP use, we found that neither flow duration 
nor cycle length significantly change over time. As the local balance between fibrinolysis 
and clotting processes in the endometrium control the volume and duration of menstrual 
bleeding and hypothalamic/pituitary hormones control menstrual cycle length, we postulate 
that IBD likely does not affect the local endometrial environment or hormone release. If 
endometrial thickness, an important determinant of fertility and in vitro fertilization (IVF) 
success, and hypothalamic/pituitary hormone release are truly unaltered in IBD this would 
correlate with the normal fertility rates reported in the literature for women with IBD who 
have not undergone surgery (26, 27). It would also suggest that women with IBD 
undergoing IVF are not at decreased odds for endometrial implantation or IVF success.
Our time analysis did show cycle regularity to change significantly over time wherein more 
regular cycles were found for each year of greater disease duration. For young women 
desiring natural pregnancy this is an important finding as it can reassure them that over time 
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their cycles should become more predictable. Although IBD treatment and disease control 
may play a role in this, we found that cycle regularity improved regardless of disease 
activity and after controlling for changes in BMI. We postulate, therefore, that women with 
incident IBD may experience unique stressors which early in their disease course adversely 
impact menstruation and over time are reduced. Perceived stress as well as psychological 
distress and altered sleep habits have all been associated with menstrual-related problems 
(28, 29). Further studies are needed to determine whether the prevalence of these factors 
differs in patients with newly diagnosed versus established IBD and whether they impact the 
menstrual cycle.
Before adjusting for other medication use we found cycle regularity to be associated with 
steroid use wherein exposure to steroids was associated with an increased risk for irregular 
cycles. After controlling for exposure to thiopurines and anti-TNFα agents, steroid use was 
not significantly associated with any menstrual cycle outcomes assessed. This suggests that 
the detrimental effects of steroids on the menstrual cycle are modified by use of a thiopurine 
or anti-TNFα agent and provides an additional reason to maximize use of steroid-sparing 
agents.
Finally, we found HRQOL in our population to be significantly associated with cycle 
regularity. Women with “fairly regular” and “irregular” cycles had lower IBDQ scores 
compared with those with regular cycles. This suggests that menstrual cycle predictability 
may be an important contributor to HRQOL in women with IBD and that the return of 
regular menstrual cycles should be assessed along with other outcomes when determining 
treatment efficacy.
Although this is the first study to describe menstrual cycle characteristics in women with 
newly diagnosed IBD it does have several significant limitations. First, the mean age of our 
cohort was 41.5; therefore, the menstrual cycle changes reported by many women may have 
been related to normal aging. To control for this we compared women ages 40 and younger 
to women over age 40 and found that other than changes in duration of flow there were no 
significant differences in menstrual cycle changes between the two groups. Age 40 was 
chosen as a cut-off based on prior data suggesting that ovarian changes typically begin in the 
the mid-30s and that menstrual cycle changes are common from about age 35 to menopause 
(30, 31). Another limitation of the study is the retrospective method by which changes in 
menstrual function were assessed which opens the possibility for recall bias. Furthermore, 
differences in the attention paid to changes in menstrual cycle among subjects and the 
subjective nature of our endpoints may have influenced our results. We also recognize that 
co-morbidities such as endometriosis and polycystic ovarian syndrome, which are common 
among young women and for which we did not assess, may have confounded our results. 
Future studies which prospectively assess for menstrual cycle changes, which control for 
gynecologic disorder confounders, and which include healthy age-matched controls are 
needed to verify our findings and determine whether women with IBD experience higher 
rates of menstrual cycle changes and irregularities compared to the general population.
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Conclusions
Using an incident cohort of IBD we found that many women may experience changes in 
their menstrual cycle as part of their initial disease presentation. For women with co-morbid 
dysmenorrhea intensification of menstrual pain and lengthening in the duration of pain in the 
year prior to IBD diagnosis are common. Further studies are needed to determine whether 
this is due to common pathophysiologic mechanisms between IBD and dysmenorrhea or to 
symptom overlap and confusion. In our longitudinal analysis we found that in general, 
menstrual cycle regularity improves over time in women with IBD. However, steroid use is 
associated with more irregular cycles even after adjusting with propensity scores. Women 
with IBD should be counseled about these potential changes to the menstrual cycle due to 
their disease and/or its treatments given the importance of menstrual cycle regularity on 
fertility and overall well-being.
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Table 1
Study Population Characteristics
Characteristic N (%)
Disease Subtype
 CD 61 (50.4)
 UC/IC 48 (39.7)
 Unknown or data missing 12 (9.9)
Race
 Black or African American 4 (3.7)
 White 98 (89.9)
 More than one race 1 (0.9)
 Other 5 (4.6)
 Refused 1 (0.9)
Marital status
 Married 34 (28.1)
 Single/Never married 57 (47.1)
 Divorced or separated 18 (14.9)
 Cohabitating 8 (6.6)
 Widowed 4 (3.3)
OCP use in the year before diagnosis (yes) 29 (26.6)
Medication use at enrollment
 5-aminosalicylate 79 (72.5)
 Antibiotic 29 (26.6)
 Steroid 58 (53.2)
 Azathioprine/6-mercaptopurine 9 (8.26)
 Anti-TNF 7 (6.42)
Characteristic Mean (SD)
Age 41.5 (15.7)
BMI 27.1 (7.3)
Disease activity score
 HBI (CD) 4.0 (3.8)
 SCCAI (UC/IC) 3.3 (2.9)
IBDO score
 CD 160.6 (34.0)
 UC/IC 163.4 (33.4)
Symptom inventory scorea
 CD 19.4 (8.3)
 UC/IC 20.6 (7.6)
aCalculated form the total of 46 possible symptoms.
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Table 2
Menstrual Cycle Characteristics at Baseline
Characteristic
Median age at menarche, yr 13.8
Mean duration of flow (days) (SD) 5.1 (1.6)
Mean cycle interval (days) (SD) 28.1 (11.5)
Characteristic N (%)
Severe pain with menstruation 48 (39.7)
Regularity of menstrual cycle
 Regular 73 (60.3)
 Fairly regular 35 (28.9)
 Irregular 10 (8.3)
 Do not know 3 (2.5)
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Table 3
Changes in Menstrual Cycle in the Year Before Diagnosis
Characteristic N (%) 95% Confidence Interval
Change in cycle interval 30 (24.8) 17.1–32.5
 Increased 10 (8.3) 3.4–13.2
 Decreased 7 (5.8) 1.6–10.0
 Irregular 11 (9.1) 4.0–14.2
 Data missing 2 (6.7) 2.2–11.1
Change in duration of flow 25 (20.7) 13.5–27.9
 Increased 5 (4.1) 0.6–7.6
 Decreased 11 (9.1) 4.0–14.2
 Irregular 7 (5.8) 1.6–10.0
 Data missing 2 (8.0) 3.2–12.8
Change in intensity of menstrual paina 19 (15.7) 9.2–22.2
 Increased 16 (13.2) 7.2–19.2
 Decreased 3 (2.5) 0–5.3
Change in duration of menstrual paina 15 (12.4) 6.5–18.3
 Increased 12 (9.9) 4.6–15.2
 Decreased 3 (2.5) 0–5.3
aAmong women with beseline dysmenorrhea only.
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Table 4
Changes in Menstrual Cycle Over Time
Response Variable Estimate P
Entire cohort
 Duration of flow Year −0.1 0.29
Steroid use 0.13 0.48
Anti-TNFα −0.01 0.96
Azathioprine/6-MP −0.07 0.79
 Length of cycle Year −0.37 0.21
Steroid use −0.21 0.73
Anti-TNFα −0.05 0.95
Azathioprine/6-MP 0.06 0.94
 Regularity of cycle Year 1.26 <0.0001
Steroid use −0.93 0.08
Anti-TNFα 0.44 0.52
Azathioprine/6-MP 0.16 0.78
 Pain with menses Year 0.06 0.83
Steroid use 0.21 0.61
Anti-TNFα −1.23 0.20
Azathioprine/6-MP −0.29 0.67
 Change in intensity of menstrual pain Year −0.25 0.55
Steroids −0.12 0.81
Anti-TNFα −0.20 0.80
Azathioprine/6-MP 0.09 0.93
 Change in duration of menstrual pain Year −0.17 0.74
Steroids 0.47 0.42
Anti-TNFα 0.51 0.62
Azathioprine/6-MP 1.50 0.20
Patients with CD
 Duration of flow HBI score −0.05 0.38
 Length of cycle HBI score −0.56 0.10
 Change in duration of flow HBI score −0.32 0.01
 Change in length of cycle HBI score −0.19 0.06
 Change in intensity of menstrual pain HBI score 0.12 0.41
 Change in duration of menstrual pain HBI score 0.18 0.19
Patients with UC/IC
 Duration of flow SCCAI score −0.002 0.96
 Length of Cycle SCCAI score 0.01 0.92
 Change in duration of flow SCCAI score −0.16 0.25
 Change in length of cycle SCCAI score −0.24 0.08
 Change in intensity of menstrual pain SCCAI score 0.3 0.10
 Change in duration of menstrual pain SCCAI score 0.27 0.23
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6-MP, 6-mercaptopurine.
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Table 5
Changes in IBDQ Score by Menstrual Cycle Factors
Variable Estimate P
Year 8.17 <0.0001
Regularity −7.22 0.04
Pain with menses −0.16 0.96
Change in intensity of menstrual pain −10.12 0.13
Change in duration of menstrual pain −1.82 0.68
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